surmount-1 tirzepatide weight loss percent 72 weeks (ZEPBOUND) Approved for Chronic Management in Adults with Obesity ✨ The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 kg/ m2 or Presented today at #ECO2026 ⤵️
Description
If you consistently want to inject early, ask your provider about a dose adjustment rather than increasing frequency
A persons health and quality of life are negatively impacted by obesity, as well as the cost of healthcare for individuals, nations, and the world as a whole
If your provider recommends any form of tirzepatide, you want to know what tirzepatide side effects are, along with its warnings, contraindications, and potential drug interactions
Would you like a sample intake plan you can use with your clinician?
[DOI] [PubMed] [Google Scholar] 79.Baser O, Rodchenko K, Vivier E, Baser I, Lu Y, Mohamed M
